Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia

AIMS: Two anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been approved for the treatment of hypercholesterolaemia in certain patients. We reviewed data from Phase 3 studies to evaluate the efficacy and safety of these antibodies. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouni‐Berthold, Ioanna, Descamps, Olivier S., Fraass, Uwe, Hartfield, Elizabeth, Allcott, Kim, Dent, Ricardo, März, Winfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099564/
https://www.ncbi.nlm.nih.gov/pubmed/27478094
http://dx.doi.org/10.1111/bcp.13066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099564/
https://www.ncbi.nlm.nih.gov/pubmed/27478094
http://dx.doi.org/10.1111/bcp.13066

Ejemplares similares